MedPath

Calcium and Lipid Metabolism

Not Applicable
Completed
Conditions
Obesity
Registration Number
NCT00686192
Lead Sponsor
USDA, Western Human Nutrition Research Center
Brief Summary

We hope to determine if supplementing the diet of women who habitually consume low levels of calcium, with 1500 mg of calcium a day for three months will increase fat oxidation and decrease fat storage. We will also measure concentrations of lipids, glucose, hormones and enzymes associated with fat and carbohydrate metabolism to determine alterations and mechanism of the metabolic changes.

Detailed Description

The incidence of obesity has rapidly increased in recent years and reached epidemic proportions in the United States. Recent epidemiological data has shown an inverse relationship between calcium intake and body fat and emerging research suggests that inadequate dietary calcium consumption may increase obesity. Studies in mice have shown that an increase in dietary calcium consumption creates a shift in the utilization of energy stores from carbohydrates to fat and a shift in the partitioning of energy from storage (as fat) to expenditure (as heat).

We will give 1500 mg of calcium a day for three months to women who habitually consume low levels of dietary calcium. The following measurements will be made before and after calcium supplementation: body fat by DEXA, lipolysis by infusion of stable isotopes of 1,1,2,3,3-\[2H5\] glycerol , hepatic glucose production by infusion of stable isotopes of 6,6-\[2H2\] glucose, lipogenesis by measurement of fatty acid synthase activity (14C radiochemical assay) , mRNA expression ( Real Time Polymerase Chain Reaction) and protein content (ELISA), indirect calorimetry measurement of non-protein respiratory quotient (NPRQ), energy expenditure, fat and carbohydrate oxidation. Serum calcium, glucose, cholesterol, triglycerides, LDL, HDL, parathyroid hormone, leptin, free fatty acids, adiponectin, 1,25(OH)2D, 25(OH)D and urinary calcium excretion will also be measured.

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
15
Inclusion Criteria
  • BMI between 25 and 30 kg/m2
  • Taking oral contraceptives
  • Having regular menses
Exclusion Criteria
  • Pregnant
  • History of metabolic bone, renal or thyroid disease,
  • History of diabetes mellitus, or gestational diabetes mellitus
  • Cigarette smoking
  • Self-administration of calcium supplements
  • Regular aerobic activity, i.e. jogging > 1 mile/day

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
Lipolysis by infusion of stable isotopes of 1,1,2,3,3-[2H5] glycerol0 and 3 months
Secondary Outcome Measures
NameTimeMethod
Hepatic glucose production by infusion of stable isotopes of 6,6-[2H2] glucose0 and 3 months
Lipogenesis by measurement of fatty acid synthase activity (14C radiochemical assay) , mRNA expression ( Real Time Polymerase Chain Reaction) and protein content (ELISA)0 and 3 months
Indirect calorimetry measurement of non-protein respiratory quotient (NPRQ), energy expenditure, fat and carbohydrate oxidation0 and 3 months
Serum calcium, glucose, cholesterol, triglycerides, LDL, HDL, parathyroid hormone, leptin, free fatty acids, adiponectin, 1,25(OH)2D, 25(OH)D0 and 3 months
urinary calcium and sodium excretion0 and 3 months

Trial Locations

Locations (1)

San Francisco General Hospital

🇺🇸

San Francisco, California, United States

San Francisco General Hospital
🇺🇸San Francisco, California, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.